|

Tislelizumab (BGB-A317) Clinical Trials

3 actively recruiting trials across 1 location

Pipeline

Phase 1: 1Phase 2: 2

Top Sponsors

  • Oncomatryx Biopharma S.L.1
  • Beijing Friendship Hospital1
  • BeiGene1

Indications

  • Cancer3
  • MSI-H/dMMR Solid Tumors1
  • Advanced Solid Tumor1
  • MCRC1

Other2 trials

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
Phase 2
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2

Boston, Massachusetts1 trial

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Beth Israel Deaconess Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.